Approval · Notice of Compliance 22773 · 2019
CEFPROZIL TABLETS: Notice of Compliance 22773
Issued October 10, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22773
- Date
- October 10, 2019
- Company
- Ranbaxy Pharmaceuticals Canada Inc.Brampton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Admin
- Reason
- Labelling update to match licensor
- Canadian reference product
- CEFZIL (Bristol-Myers Squibb Canada)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CEFPROZIL TABLETS | Not yet assigned | — |